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NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 
PUBLIC HEALTH DRAFT GUIDANCE 
Hepatitis B and C: ways to promote and offer 
testing to people at increased risk of infection  
Introduction: scope and purpose of this draft guidance 
What is this guidance about? 
This guidance aims to ensure more people at increased risk of hepatitis B and C 
infection are tested. The recommendations cover: 
 Awareness-raising among:  
 the general population 
 health professionals and others providing services for those at 
increased risk of hepatitis B or C infection 
 those at increased risk.  
 Testing: 
 in primary care 
 in prisons, including youth offender institutions 
 within drugs services. 
 Contact tracing for hepatitis B. 
 Delivering and auditing hepatitis B vaccination. 
 Laboratory services for hepatitis B and C tests.  
 Commissioning hepatitis B and C testing and treatment services. 
This guidance does not provide detail on treatments for hepatitis B or C. (For 
treatment recommendations see other NICE guidance listed in section 7.)  
Who is this guidance for? 
The guidance is for: 
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 Commissioners and providers of public health services, hepatitis testing and 
treatment services and laboratory services for hepatitis B and C testing. 
 Local organisations providing services for children and adults at increased risk of 
chronic hepatitis B and C, including those in the NHS, local authorities, prisons 
and drugs services. It is also for voluntary sector and community organisations 
working with those at increased risk.  
The guidance may also be of interest to groups at increased risk of viral hepatitis, for 
example, migrant populations from countries with an intermediate or high prevalence 
of hepatitis B infection or people who use drugs and their families. In addition, other 
members of the public may have an interest.  
Why is this guidance being produced? 
The Department of Health (DH) asked the National Institute for Health and Clinical 
Excellence (NICE) to produce this guidance. 
The guidance should be implemented alongside other guidance and regulations (for 
more details, see sections 4 and 7 on implementation and related NICE guidance 
respectively).  
How was this guidance developed? 
The recommendations are based on the best available evidence. They were 
developed by the Programme Development Group (PDG).  
Members of the PDG are listed in appendix A.  
The guidance was developed using the NICE public health programme process. See 
appendix B for details.  
Supporting documents used to prepare this document are listed in appendix E. 
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What evidence is the guidance based on? 
The evidence that the PDG considered included: reviews of the evidence, economic 
modelling and the testimony of expert witnesses. Further detail on the evidence is 
given in the considerations section (section 3) and appendices B and C.  
In some cases the evidence was insufficient and the PDG has made 
recommendations for future research.   
More details on the evidence on which this guidance is based, and NICE’s 
processes for developing public health guidance, are on the NICE website. 
Status of this guidance 
This is draft guidance. 
This document does not include all sections that will appear in the final guidance. 
NICE is now inviting comments from stakeholders (listed on our website). 
Note that this document is not NICE's formal guidance on hepatitis B and C 
testing. The recommendations made in section 1 are provisional and may 
change after consultation with stakeholders. 
The stages NICE will follow after consultation are summarised below.  
 The Group will meet again to consider the comments and any additional evidence 
that has been submitted. 
 After that meeting, the Group will produce a second draft of the guidance. 
 The draft guidance will be signed off by the NICE Guidance Executive.  
For further details, see ‘The NICE public health guidance development process: An 
overview for stakeholders including public health practitioners, policy makers and the 
public (second edition, 2009)’.  
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The key dates are:  
Closing date for comments: 8 August 2012. 
Next PDG meeting: 12 and 13 September 2012. 
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1 Draft recommendations  
The Programme Development Group (PDG) considers that the recommended 
measures and approaches are cost effective. 
The evidence statements underpinning the recommendations are listed in appendix 
C.  
For the gaps in research, see appendix D. 
Pre-requisites 
The recommendations are based on the assumption that hepatitis tests are delivered 
according to current best practice and are offered as part of a care pathway covering 
diagnosis and treatment. 
The recommendations also assume that all frontline healthcare staff involved in 
testing for hepatitis B and C, including non-clinical staff, are trained in diversity 
issues. This means they are able to challenge the stigma of, and dispel the myths 
surrounding, hepatitis and testing for hepatitis. It also means they should be able to 
create a physical and emotional environment where both children and adults feel at 
ease.  
Testing 
The recommendations assume that appropriate pre- and post-test discussions take 
place when testing for hepatitis B and C. The offer of a test should also: 
 be accompanied by an agreed mechanism for getting the result to the person 
being tested  
 be phrased in a way that suits a person’s age and culture and be delivered in a 
non-judgmental, respectful way 
 take into account potential barriers to testing such as the potential stigma 
associated with it or lack of access to services 
 include information to enable people to make informed choices about their care. 
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Treatment 
Current best practice guidelines on managing hepatitis B and C are available from 
the European Association for the Study of the Liver (EASL). NICE has recommended 
a number of drugs to treat hepatitis B and C, see section 7 for details. 
Whose health will benefit? 
Children and adults at increased risk of hepatitis B or C compared to the general UK 
population. This includes: 
 People born or brought up in a country with an intermediate (more than 2.0%) or 
high (more than 8.0%) prevalence of chronic hepatitis B (and who may also be at 
increased risk of hepatitis C). This includes all countries in Africa, Asia, the 
Caribbean, Central and South America, Eastern and Southern Europe, the Middle 
East and the Pacific islands. 
 People who have injected recreational drugs (no matter how rarely) or who share 
drugs paraphernalia, such as straws (used for snorting drugs) or needles. 
 Men who have sex with men, commercial sex workers and anyone who has 
unprotected sex and frequently changes sexual partners.  
 Prisoners and young offenders. 
 Children and young people living in care homes. 
 Close contacts of someone known to be chronically infected with hepatitis B or 
hepatitis C. 
 Babies born to mothers infected with hepatitis B or C. 
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Recommendation 1 Awareness-raising about hepatitis B and C 
among the general population 
Who should take action? 
Commissioners and providers of national public health services working in 
partnership with:  
 other government departments allied to health 
 local commissioners and providers of public health services 
 the commercial sector 
 national voluntary sector, not-for-profit and non-governmental organisations. 
What action should they take? 
 Identify and make use of existing campaign messages and resources on hepatitis 
B and C to raise awareness of these infections. Include ideas from other 
countries, where available and appropriate. If nothing is available, generate 
messages and resources. These should include up-to-date information on the: 
 availability of effective treatment 
 benefits of testing and treatment, including the fact that earlier 
diagnosis and treatment  can help prevent complications and serious 
illness such as liver disease 
 main routes of infection and  transmission  
 mostly asymptomatic nature of chronic infection (that is, there are 
very few symptoms in the early stages). 
 Ensure awareness-raising campaigns address common misconceptions about the 
risk of hepatitis B and C that can act as a barrier to testing. This includes the belief 
that treatments are not effective, or that treatment is not needed until the illness is 
advanced. Campaigns should also make it clear that testing and treatment is 
confidential and address any stigma surrounding these infections.  
 Ensure messages to raise awareness of hepatitis B and C are integrated, where 
possible and relevant, within other health promotion campaigns or are used to 
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support interventions to prevent liver disease. Ensure they are consistent, clear 
and culturally appropriate.   
 Ensure national awareness-raising activities take into account cultural, religious 
and group norms and needs, in terms of message format, the medium and the 
language used. For example, translated information should be provided to 
address the needs of non-English-speaking groups at increased risk. 
Recommendation 2 Awareness-raising among health professionals 
and others providing services for those at increased risk of 
hepatitis B or C 
Who should take action? 
 Directors of public health. 
 NHS deaneries or other organisations responsible for the development of health 
and social care staff. 
What action should they take? 
 Ensure there is an ongoing education programme for professionals providing 
health and social care services for those at greatest risk of hepatitis B or C. This 
includes: 
 clinical and non-clinical staff in primary, secondary and tertiary care 
 nurses, health visitors and midwives 
 those working in drugs services 
 prison staff 
 staff in voluntary and community organisations that care for or 
support migrant populations or people who inject drugs  
 genitourinary and HIV clinics. 
 Ensure the education programme is tailored to each target group, as appropriate. 
It should include accurate, up-to-date detail on the: 
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 routes of hepatitis B and C transmission, the clinical consequences 
of infection and treatment options 
 local groups at increased risk 
 people from groups at increased risk who have been offered a test, 
have been tested or have refused a test   
 diagnostic tests and samples required  
 way to interpret results 
 social and cultural barriers to testing and treatment (for example, 
people’s fear of stigma and staff attitudes towards hepatitis B and C) 
 importance of confidentiality 
 additional support and advice that people taking a test may need (for 
example, they may need advice on the impact a positive test may 
have on their employment prospects or insurance) 
 local referral pathways, including who to refer to and how 
 role of other professionals in awareness-raising, identifying cases 
and helping people complete treatment 
 importance of testing at-risk populations whenever an appropriate 
opportunity arises 
 importance of repeat testing for those who continue to adopt high-
risk behaviours 
 availability and indication for hepatitis B vaccination. 
 Consider linking awareness-raising activities with existing education for health and 
social care professionals. This could take a variety of forms, for example, it could 
be offered as a taught or an electronic learning module.  
 Deaneries in each region should ensure doctors and nurses involved in testing for 
hepatitis B and C partake in a programme of continuing professional development 
to develop their knowledge, skills and ability in this area. 
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 Directors of public health, in collaboration with the local deanery should use staff 
annual appraisals and personal development plans to reinforce training and 
education on hepatitis B and C. 
Recommendation 3 Awareness-raising among those at increased 
risk of hepatitis B or C infection 
Who should take action? 
 Directors of public health.  
 Local organisations providing services for children and adults at increased risk 
including the NHS (primary, secondary and tertiary care), local authorities and 
community and voluntary sector organisations with a remit for these groups.  
 Other local and national organisations involved in hepatitis testing or treatment. 
What action should they take? 
 Directors of public health should ensure there is a local programme of awareness-
raising about hepatitis B and C among groups at increased risk. 
 Local organisations should provide awareness-raising material tailored to these 
groups’ needs. In addition to the information outlined in recommendation 1, this 
should:  
 tell them how and where to access local testing services 
 describe what having a hepatitis test involves 
 address the needs of non-English-speaking at-risk groups, for 
example, by providing translated information 
 be appropriate for all ages.   
 Local organisations should, where possible, encourage people from groups at 
increased risk who have experienced viral hepatitis to contribute to awareness-
raising activities.  
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 Local organisations should run awareness-raising sessions to promote hepatitis B 
and C testing in venues and events frequented by groups at increased risk. 
Examples of possible venues include: faith centres, NHS and non-NHS drugs 
services, GP surgeries and prisons. Examples of relevant events could include 
cultural activities aimed at people from black and minority ethnic groups. 
Recommendation 4 Testing for hepatitis B and C in primary care  
Who should take action? 
Primary care practitioners.  
What action should they take? 
 Be aware of groups of adults and children who are at increased risk of infection 
from hepatitis B and C (see Whose health will benefit? at the beginning of this 
section). Whenever an appropriate opportunity arises, offer them a hepatitis B and 
C test. 
 Offer a hepatitis B and C test to everyone who has newly registered, and who is 
part of an at-risk group. This includes both adults and children from countries with 
an intermediate or high prevalence of hepatitis. It also includes adults who are 
newly registered with the practice who have injected drugs. (Ask all adults 
whether or not they have ever injected drugs once they have registered with the 
practice.). 
Recommendation 5 Testing for hepatitis B and C in prisons 
Who should take action? 
 Local infection control team. 
 NHS hepatitis treatment services. 
 Prison healthcare services, including services for young offenders.  
 Public Health England units. 
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What action should they take? 
 Prison healthcare services should develop a viral hepatitis policy in conjunction 
with the hepatitis treatment service, the Public Health England unit, local infection 
control team and prison healthcare service commissioners.  
 Prison healthcare services should designate a member of staff as the viral 
hepatitis lead for the prison or youth offender service. The lead should have the 
knowledge and skills needed to promote hepatitis B and C testing and treatment. 
 The NHS treatment service lead for viral hepatitis (for example, this may be the 
community hepatitis nurse) should develop a care pathway for prisoners infected 
with hepatitis B or C. This should be developed in conjunction with prison 
healthcare services, drugs services, the Public Health England unit and prison 
healthcare service commissioners. As part of the care pathway: 
 Any suspected or confirmed cases should be reported to, and 
managed by, the local hepatitis treatment services, in liaison with 
prison healthcare services. 
 Investigations and follow-up should be undertaken within the prison 
(based on the in-reach model), wherever practically possible. 
 Prisoners should be treated by staff from the local hepatitis treatment 
service (the prison should support this by, for example, giving these 
staff security clearance). 
 Prison healthcare services should ensure: 
 On entry into a prison, prisoners at increased risk of hepatitis B or C 
infection are offered a test. This could be offered when prisoners are 
being offered a hepatitis B vaccination (for the vaccination schedule 
refer to the Green book).   
 All prisoners are given information on hepatitis B and C and how to 
access confidential testing within 7 days of their arrival.   
 A mechanism is in place for prisoners to be tested for hepatitis B and 
C at any point during their stay in prison. 
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 Mechanisms are in place to give prisoners the results of a hepatitis B 
or C test, regardless of their location when the test results become 
available. 
 Staff involved with testing prisoners for hepatitis B and C are 
appropriately trained and have up-to-date information about the 
infections, including treatments and local care pathways. They 
should also respect the need for confidentiality when dealing with 
these issues. 
 The NHS treatment service lead for viral hepatitis in prisons should ensure prison 
healthcare services have contingency, liaison and handover arrangements before 
any prisoner being treated for hepatitis is transferred between prisons or released. 
Other agencies working with prisoners or detainees should also be involved in this 
planning. 
 The person responsible for managing a prisoner’s hepatitis treatment should 
ensure their continuity of care if they are transferred, or following their release. If 
necessary, prisoners due to be transferred should be retained on medical hold to 
help them complete their treatment.  
Recommendation 6 Testing for hepatitis B and C within drugs 
services 
Who should take action? 
 Drugs services including drug and alcohol action teams. 
 Hepatology service commissioners. 
 NHS hepatitis treatment services. 
 Public Health England units.  
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What action should they take? 
 Commissioners from all of the above services should agree a local care pathway 
for people with hepatitis B and C who attend drugs services. Where possible, the 
pathway should include the possibility of providing hepatitis B and C treatment 
services in community settings.  
 Medical staff should use their clinical judgment to determine who is suitable for 
hepatitis B or C treatment in a community setting. 
 Drugs services should designate a member of staff as the hepatitis lead. The lead 
should have the knowledge and skills to be able to promote hepatitis B and C 
testing and treatment. 
 Drugs services should have access to dried blood-spot and specialist phlebotomy 
services to help with testing and treatment for hepatitis B and C, particularly for 
people who inject drugs.  
 Drugs services should be able to call on trained peers of people who are at 
increased risk of hepatitis B and C to promote testing and support them during 
testing and treatment. The people providing peer support should also be given 
support (for further information see NICE guidance on community engagement). 
 Drugs services staff should: 
 Be trained to undertake dried blood-spot testing if carrying out 
hepatitis B and C testing.  
 Have the knowledge, confidence and skills to be able to promote the 
benefits of hepatitis testing, discuss the symptoms and the 
implications of a positive or a negative test.  
 Routinely check all clients, including those aged under 18, for 
hepatitis B and C risk factors. 
 Offer a hepatitis B and C test to all clients with any risk factors. If the 
client declines the offer, staff should explore their barriers to being 
tested, with the aim of dispelling their concerns and helping them to 
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get tested. They should also offer them information and peer support 
with a view to reviewing their decision.   
 Consider giving information on hepatitis B and C testing and 
treatment to any client they are concerned about, whether or not the 
client has disclosed that they inject drugs or are involved in any 
other high-risk behaviour.  
Recommendation 7 Contact tracing for hepatitis B  
Who should take action? 
Public Health England units.  
What action should they take? 
 Be directly accountable for tracing the close contacts of all notified cases of 
hepatitis B. 
 Oversee other local organisations that undertake close contact or household 
contact-tracing and regularly audit their activities to ensure they follow recognised 
national standards. For example, contacts may need to be vaccinated and, where 
relevant, referred for appropriate treatment. 
Recommendation 8 Delivering and auditing hepatitis B vaccination 
Who should take action? 
Directors of public health. 
What action should they take? 
 Ensure existing recommendations on hepatitis B vaccination, as detailed in the 
Green book and NICE guidance on reducing the differences on the uptake of 
immunisations, are implemented locally. 
 Audit the hepatitis B vaccination programme for babies to gauge uptake. Note 
whether the babies involved were given all required doses, whether the doses 
were given at the right time and whether the babies were tested post-vaccination. 
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Also note vaccination failure rates among babies of chronically infected mothers. 
This audit should be carried out on an annual basis. 
Recommendation 9 Laboratory services for hepatitis B and C tests 
Who should take action? 
Commissioners of laboratory services offering hepatitis B and C tests. 
What action should they take? 
 Ensure laboratory services offering hepatitis B and C tests: 
 have Clinical Pathology Accreditation  
 can support the range of samples used for hepatitis B and C tests 
(for example, dried blood-spot or venipuncture samples) 
 can provide the full spectrum of tests needed to determine infection  
 can deliver the results within 2 weeks (for suspected acute hepatitis 
B, results should be delivered in 1 day, in line with Health Protection 
Agency standards) 
 can automatically perform an assay for detection of hepatitis C virus 
in the sample if the sample is antibody positive (for example, the 
polymerase chain reaction assay). 
 In accordance with national legislation, ensure local public health services are 
notified of all newly diagnosed cases of acute and chronic viral hepatitis B and C. 
 Provide the organisation or person requesting a test with an accurate 
interpretation of the laboratory results and guidance on how to manage positive 
results. 
 Ensure laboratory services can provide accurate data on the following: 
 number of tests performed 
 referral source of samples (for example, primary care, secondary 
care, drug and alcohol services, prisons)  
 exposure category (where provided) 
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 number of positive tests.  
Recommendation 10 Commissioning hepatitis B and C testing and 
treatment services 
Who should take action? 
Commissioners of hepatitis testing and treatment services. 
What action should they take? 
 Undertake a regular needs assessment and a regular audit of hepatitis B and C 
services as part of the agreed local care pathway. 
 Audit the uptake of testing and outcomes, including the number of:  
 hepatitis B and C tests performed  
 positive tests  
 people who test positive who are referred to a specialist 
 people who see the referral specialist 
 people who test positive and are offered therapy 
 people who test positive and are being treated 
 people with hepatitis C who achieve a sustained virological 
response.  
 Working with services that provide hepatitis B and C tests and treatment in both 
primary and secondary care, develop and commission a fully integrated care 
pathway. This should: 
 take into account the needs of all local groups at increased risk of 
hepatitis B or C, including those who are in prison  
 consider all venues where testing and treatment services are, or 
could be offered, to ensure continuity of care (such as pharmacy 
testing and outreach testing and treatment) 
 consider the broader health and psychosocial needs of those at 
increased risk, for example, their nutritional, housing and financial 
needs 
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 ensure primary and secondary care staff are educated and trained in 
hepatitis B and C testing and treatment, as appropriate. 
 Encourage the development of locally enhanced services for hepatitis B and C in 
areas where the population includes a higher than average number of people at 
increased risk (see ‘Whose health will benefit?’ at the beginning of this section).  
 Ensure men who have sex with men are tested for hepatitis B and C, especially 
those who are HIV-positive.  
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2 Public health need and practice 
Hepatitis C  
Hepatitis C is a blood-borne viral infection transmitted through contact with infected 
blood, for example, by sharing infected injecting equipment. It can also be 
transmitted through other body fluids. Around 70–75% of people who are infected 
develop a chronic condition and are at risk of liver failure and liver cancer.  
In the UK, an estimated 216,000 people are thought to be chronically infected 
(Health Protection Agency 2011b). Around 161,000 of them live in England  with 
39,000, 12,000 and 4000 chronic cases in Scotland, Wales and Northern Ireland 
respectively (Health Protection Agency 2011b). The estimate for Scotland relates to 
the end of 2009, while the figures for England, Wales and Northern Ireland date to 
the mid-2000s. There is, therefore, considerable uncertainty about the current UK 
situation. 
In England, 48,946 infections were diagnosed by the end of 2005, representing only 
30% of the estimated chronic burden at that point. It is estimated that only around 
12,400 of those people were treated between 2006 and 2008 (Health Protection 
Agency 2011b).  
The burden of hepatitis C, in terms of hospitalisations, registrations for liver 
transplant and deaths from liver cancer, is steadily increasing throughout the UK. In 
England, the rates of ‘end stage’ disease caused by hepatitis C are likely to increase, 
if diagnosis and treatment rates do not improve (Health Protection Agency 2011b). 
Risk factors 
In England, injecting drug use is the main cause of hepatitis C infection. Around 44% 
of the estimated number of people who are chronically infected inject drugs, 43% are 
former injectors, 5.6% are of South Asian descent and have never injected and 7.3% 
of cases have no history of injecting (Harris et al. 2011a). Similarly, 90% of the total 
laboratory reports including risk information attribute infection to injecting drug use 
(Health Protection Agency 2011c).   
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The prevalence of chronic disease varies by region. It is highest in London and the 
North West and increases with an increasingly aged population (Harris et al. 2011b). 
This is confirmed by data from the 2010 Unlinked Anonymous Monitoring (UAM) 
survey of people who inject drugs and attend specialist services (Harris et al. 2011b). 
The UAM survey suggests that more of this group are being tested (83% reported 
having  a voluntary test for hepatitis C, compared to 40% in 2000). However, the 
numbers being tested is still low. Only 55% of those who tested positive were aware 
they were infected before they had the test. 
Hepatitis B 
Hepatitis B infection is transmitted through contact with infected blood, as well as 
perinatally from mother to child.  
Some adults can clear the infection naturally. However, the risk of progression 
depends on the age when someone is infected. About 85% of infections in newborns 
and 4% in adults become chronic and could lead to severe liver disease (Edmunds 
et al. 1993). 
The most recent estimate from the Department of Health suggests that, in 2002, 
180,000 people in the UK might have had chronic hepatitis B (DH 2002). However, 
other organisations believe that figure may have been closer to 360,000. Currently, 
information on the hepatitis B burden in England and Wales derives from a number 
of sources:  
 laboratory reports 
 serological studies of populations covered by screening programmes (pregnant 
women and blood donors) 
 serological studies of populations at high risk (people who inject drugs) 
 sentinel surveillance 
 estimates of the size of the migrant population. 
The DH study relied on the analysis of laboratory reports sent to the Health 
Protection Agency between1995 and 2000. On the basis of the 4040 reported ’acute 
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infections’ over the period (on average, 673 reports per year), the annual incidence 
in England and Wales was estimated at around 7.4 per 100,000 people. This 
translates into around 3700 new acute infections a year and around 270 chronic 
cases per year.  
Risk factors 
Injecting drug use was the most frequently reported route of infection in the UK, 
according to the Health Protection Agency, and the number of such cases peaked in 
1998 (251 HBsAg positive and anti-HBc IgM positive cases). Homosexual contact 
was the second most frequently reported risk factor. People of South Asian origin 
also appear to be at high risk: the prevalence of acute hepatitis B among this group 
was estimated to be more than double the estimated overall incidence. Over 95% of 
chronic infections were estimated to be associated with immigration (Hahné et al. 
2004).  
Since 2000, transmission routes of acute infection have followed a similar trend. For 
2010, risk factor information (only available for 47% of acute cases) suggests the 
number of cases attributable to injecting drug use has continued to decline (Health 
Protection Agency 2011a). This is confirmed by the 2010 UAM survey, which reports 
a fall from 28% to 16% cases (Health Protection Agency 2011c). This decrease 
might be associated with an increase in the self-reported uptake of hepatitis B 
vaccine, from 35% in 2000 to 74% in 2010, among the people injecting drugs who 
were cited by the UAM survey (Health Protection Agency 2011c). 
Prevalence broken down by ethnic group  
The prevalence of hepatitis B among the population as a whole can be estimated by 
determining the prevalence of hepatitis B surface antigen (HBsAg), using data from 
the sentinel surveillance study. This study has been collecting information on 
hepatitis testing in a number of participating centres since 2002 (Health Protection 
Agency 2011d). 
In 2010, 22 sentinel centres reported that 192,664 people had undergone HBsAg 
testing and 1.6% of them had tested positive. Of those who tested positive, 0.7% had 
Hepatitis B and C: ways to promote and offer testing Consultation draft   
  Page 23 of 76 
 
an acute infection. Around three quarters of those tested could be classified into four 
broad ethnic groups: white or white-British (77.8%), Asian or Asian-British (15%), 
‘other’ or mixed ethnicity (4.3%), and black or black-British ethnicity (2.6%). The 
highest proportion of positive tests was among the ‘other’ or mixed ethnicity group 
(8.8%), followed by people of black or black-British (7.4%), Asian or Asian-British 
(2.6%) and people who were white or white-British (0.84%).  
Where information on the reason for testing was available (31.2% of the tested 
population), injecting drug use was reported in 1.7% of cases – and for 0.5% of 
those who tested positive. Sexual exposure was reported by 7.1% of those tested 
and accounted for 4.3% of the positive results. 
Antenatal screening 
Antenatal screening for HBsAg has been carried out by the Infectious Diseases in 
Pregnancy Screening Programme since 2004 (Health Protection Agency 2011a). 
The results show an increasing uptake over time (94% in 2010) but with the 
percentage of positive tests remaining about the same (0.45% in 2010).  
The sentinel surveillance identified that 24.6% (62,282) of the women who had been 
tested for HBsAg in 2010 had been tested as part of antenatal screening for HBsAg. 
Overall, 0.5% of them tested positive. Most of the 62,282 women were classified as 
white or white-British. More black or black-British (3.8%) and ‘other’ or mixed 
ethnicity (4.3%) women tested positive for HBsAg compared with their Asian/Asian-
British (0.5%) and white- counterparts (0.3%). 
Complex picture 
The information above shows a complex picture with a heterogeneously distributed 
risk of infection among children and adults, affected by country of birth, ethnicity, 
injecting drug use and sexual practices.  
National recommendations 
The national immunisation programme recommends that people from at-risk groups 
are immunised against hepatitis B. Due to an increased risk of chronic infection, 
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post-exposure immunisation is also recommended for babies born to chronically 
infected mothers (DH 2006). 
NICE recommends a number of treatments for hepatitis B and hepatitis C (see 
section 7 for related NICE guidance). If someone who is infected can be identified 
and treated early enough, their risk of developing long-term complications, such as 
cirrhosis and liver cancer, can be reduced. For those with chronic hepatitis C, early 
therapy is associated with increased and sustained virological response rates (Corey 
et al. 2010).  
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3 Considerations 
The Programme Development Group (PDG) took account of a number of factors and 
issues when developing the recommendations.  
Awareness-raising 
3.1 The PDG was aware of the potential benefit of educating all health 
professionals about hepatitis B and C but was pragmatic in its approach, 
focusing on those who were likely to be providing services. 
3.2 Recent developments in the treatment of hepatitis B and C are not 
reflected in the qualitative literature on the barriers and facilitators to 
testing. This is because much of the research was undertaken before the 
newer drugs (see section 7) were available. The Group felt that 
awareness of more effective treatments may have a positive impact on 
the uptake of testing. 
3.3 The need for awareness-raising and training on hepatitis C for health 
professionals was a key theme in the qualitative review – and was in 
accord with PDG members’ experiences. The Group heard reports of 
people having to initiate testing for viral hepatitis and liver function and 
being left with misinformation and confusion about their diagnosis, its 
consequences and treatment pathways. The Group felt it important that 
professionals working in this area had the ability to help people make 
informed choices.  
Barriers and facilitators 
3.4 There are many barriers to testing for hepatitis B and C for groups at 
increased risk of infection and many are similar for both infections. They 
include: 
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 Fear of stigma – caused by both health professionals and family or 
friends. (When defining those at increased risk of hepatitis B and C the 
PDG was mindful not to further stigmatise these groups.)   
 Knowledge and awareness in relation to the transmission of infection 
and the treatments available. The PDG was aware of a general lack of 
knowledge about hepatitis B and C, including among those promoting 
tests for these infections. Members felt that this contributed to the low 
uptake of testing among people at increased risk of infection. They also 
felt it contributed to the stigma surrounding these infections.   
 Parental fears that they will not be able to cope with the issues their 
child may face if the child is found to have hepatitis B or C. (This is 
especially the case if no appropriate information and care pathways 
have been discussed with parents.) 
 Staff attitudes and competency.  
3.5 People who may have injected drugs in the past may not want to revisit 
that part of their lives. This may be a barrier to hepatitis testing and 
treatment. The PDG felt that positive messages about treatment – 
particularly the latest and forthcoming advances – and any attempts to 
‘normalise’ testing might help reach these people. 
3.6 The PDG acknowledged that, while it is important to conduct tests in a 
timely manner, some people at increased risk may face more pressing 
issues than the need to know if they are hepatitis B or C positive. For 
example, economic, social or other health needs may be more of a priority 
for them.  
3.7 The PDG recognised the important role that immediate relatives, 
‘significant others’ and other family members may play in encouraging 
people to get tested and complete treatment. The Group also recognised 
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a role for the peers of people at increased risk in promoting hepatitis B 
and C testing and supporting them.  
3.8 The PDG noted that it was important to ensure people are not stigmatised 
by the way information on hepatitis B and C is delivered. 
3.9 Transmission of hepatitis B from mother to child may be considered 
normal among some minority ethnic communities. Although this means 
there is less stigma associated with infection among this community, the 
Group felt that acceptance of infection may adversely impact on the 
uptake of testing and treatment. It noted a lack of qualitative evidence 
about this route of transmission, suggesting a lack of awareness and the 
need for preventive education.  
3.10 In countries where there is a high prevalence of hepatitis B, employees 
may be routinely screened for infection and the stigma surrounding it may 
be higher among people from those countries.  
3.11 The PDG noted that people who inject drugs and have hepatitis C could 
be stigmatised by the injecting drug community, as a diagnosis of hepatitis 
C suggests a history of sharing paraphernalia. This is in addition to the 
stigma people who inject drugs already face.  
3.12 The PDG was mindful that offering universal testing in certain settings, 
rather than singling people out, may help reduce the stigma surrounding 
hepatitis B and C. Similarly, the stigma of having a test may be reduced 
for injecting drug users if it is possible to utilise dried blood-spot testing or 
if there is someone who specialises  in blood-taking available. (It can be 
difficult to take blood from someone whose veins have been damaged 
and can lead to multiple attempts which can prove embarrassing, not to 
mention painful.)  
3.13 The PDG discussed the need to train primary care staff in how to carry out 
pre- and post-test discussions with people at increased risk of hepatitis B 
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and C. It recognised that a barrier to the implementation of such training 
was time constraints. 
Testing 
3.14 The PDG recognised that the use of dried blood-spot testing for diagnosis 
may be more acceptable to some of the target populations than taking a 
blood sample from a vein, especially if there is poor venous access. In 
addition, more staff would probably be able to could carry out such tests, 
so helping to increase the number of people who are tested. For this 
reason, the PDG felt that the provision of both dried blood-spot testing 
and access to specialist phlebotomy would play a pivotal role in increasing 
testing uptake.  
3.15 It can be difficult to take a sample of blood from a person who has injected 
drugs, due to the damage done to their veins, which will be required to 
monitor treatment. For this reason, the PDG felt that access to specialist 
phlebotomy services would be an important aid to increasing uptake of 
treatment 
3.16 No recommendations were made on the use of a mouth swab for hepatitis 
B or C testing. The PDG recognised that this method may be more 
acceptable to some people because it is less invasive than taking blood 
from a vein. However, if an oral fluid sample was used, a blood sample 
would then be required to confirm the initial positive results, and for 
polymerase chain reaction testing for hepatitis C. 
3.17 The PDG acknowledged that different populations are at increased risk of 
hepatitis B or C. However, there is some overlap between them and, to 
simplify delivery, it made sense to recommend testing for both. 
3.18 The PDG felt that the point of entry into a hepatitis B vaccination 
programme also provides an opportunity to test those considered to be at 
increased risk for both hepatitis B and C infection. The Group was aware 
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of cases where people had repeatedly been vaccinated against hepatitis 
B but not tested for infection and had later been found to have chronic 
infection and subsequent liver damage.   
3.19 The PDG acknowledged that there may be opportunities to combine 
hepatitis B and C testing with broader, blood-borne virus prevention and 
testing activities. 
3.20 The PDG felt that there may be merit in considering other venues, such as 
pharmacies, for testing (in terms of ease of accessibility). However, there 
was no evidence to support such a recommendation.  
Limitations of the evidence 
3.21 There was little published evidence on effective interventions to promote 
and offer testing to those at increased risk of hepatitis B. There was also a 
lack of corresponding evidence for interventions addressing hepatitis C 
testing among migrants. The PDG, therefore, largely drew on practical 
experience to formulate the recommendations.  
3.22 Research has focused on hepatitis B among minority ethnic groups and 
hepatitis C among people who inject drugs. The PDG was concerned 
about the potential cross over – between infections and groups at 
increased risk (for example, drug use may be a route for hepatitis B 
transmission). Members were also concerned about people who have 
previously injected drugs, and other groups at increased risk, because 
there was no evidence on how to effectively reach them. This includes, for 
example commercial sex workers and men who have sex with men. The 
group felt that the principles of the recommendations may apply to these 
groups.  
3.23 The mapping review provided limited evidence of existing good practice 
on testing among those at increased risk.  
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Economic modelling 
3.24 The way hepatitis B and C are transmitted among different groups at 
greatest risk varies according to each group. For example, among people 
who inject drugs in the UK, in 90% of cases hepatitis C is transmitted by 
sharing injecting equipment. Among migrant groups (people from medium 
and high endemicity countries), while adult-to-adult transmission of 
hepatitis B does occur, only about 5% of such cases become chronic. The 
main transmission routes are via mother to baby and between children 
through exposure to contaminated blood. The majority of chronic 
infections of hepatitis B are acquired in the country of origin. The 
modelling analyses took these differences into account.  
3.25 There was a lack of data on interventions to increase rates of case-finding 
and treatment in prison, and on continuity of treatment from prison into the 
community. This meant it was difficult to judge the cost effectiveness of 
such interventions and treatment rates following diagnosis.  
3.26 The migration modelling was also severely hampered by lack of data on 
the prevalence of chronic hepatitis B among minority ethnic groups, the 
cost of finding infected people within these groups and treatment rates. 
3.27 The cost effectiveness of primary care interventions to promote testing for 
hepatitis B and hepatitis C among men who have sex with men was not 
formally evaluated. The PDG acknowledged the existence of other NICE 
guidance promoting testing for other infections among this group. The 
modelling undertaken showed that, where there is a reasonably high 
prevalence of undiagnosed cases of hepatitis B and C, adding a test for 
these infections when testing for HIV would be cost effective.  
Prisons 
3.28 The PDG noted a lack of evidence on interventions in specific settings, for 
example, prisons. Expert testimony was sought to address these gaps. 
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3.29 Given the prevalence of hepatitis B and the history of injecting drug use 
among the prison population, the PDG recognised the importance of 
prison as a setting for the promotion and offer of hepatitis B and C testing. 
It also acknowledged that the established hepatitis B vaccination 
programme in prisons provides an opportunity for discussing the benefits 
of being tested. 
3.30 The PDG recognised that prisons vary in numbers and types and that a 
‘one-size-fits-all’ approach on testing and subsequent treatment for 
hepatitis is not appropriate.  
3.31 The PDG was aware of problems with the transfer of medical records and 
information between prison and community settings. However, it was 
beyond the remit of this guidance to make recommendations about 
sharing health data between custodial and community providers. 
3.32 The PDG recognised the barriers to continuity of care when someone 
enters or is released from prison. However, the Group felt that these 
barriers should not be viewed as reasons not to test prisoners for 
hepatitis. 
3.33 Prison testing for hepatitis B and C is cost effective if there is continuity of 
care when someone who is infected is referred to, from or between 
prisons and treatment is seamlessly completed in at least 40% of cases. 
Prison testing would also help ensure prisoners have the same access to 
healthcare as everyone else, thus addressing health inequalities.  
3.34 The PDG was aware that a key factor impacting on treatment outcomes 
was the length of someone’s remaining stay in prison following diagnosis 
– many prisoners only live at one site for short periods of time, for 
example when on remand. 
3.35 The PDG was aware that treatment success rates are greater when 
treatment is based on an ‘in-reach’ model of care in prisons (rather than 
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escorted outpatient treatment). However, the Group acknowledged that 
the necessary security arrangements in prison could act as a barrier to 
this approach. 
Data 
3.36 The PDG acknowledged the limitations and challenges of current 
surveillance systems for hepatitis B and C. The Group considered that the 
collection and collation of robust, service-level data on testing and 
treatment services was important for both monitoring and developing 
services.  
3.37 The PDG discussed the need for a comprehensive hepatitis B and C 
database holding details on people who have been tested and treated and 
on those identified as being at increased risk but who have refused to be 
tested. It considered that an integrated system, bridging different 
healthcare providers and capturing a range of data, was the ideal. (It 
could include demographic details, exposure category, testing information, 
laboratory results, referrals and treatment outcomes.) It was felt that there 
needed to be a balance between the burden of collecting data and the 
value of that data. The Group acknowledged that it would be resource-
intensive. Members also noted that such databases have been developed 
in other countries and have proven to be effective. 
3.38 The PDG moved away from a focus only on those with chronic hepatitis 
infection, as regardless of whether infection is acute or chronic it 
contributes to transmission rates.  
3.39 Snorting drugs and sex have been recently recognised as routes for 
hepatitis C infection about which there is little data.  
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Other issues 
3.40 The PDG discussed how hepatitis B and C compares with other diseases, 
such as HIV and coronary heart disease, in terms of the resources 
available for treatment. 
3.41 It may not always be obvious when a particular group is at increased risk 
of hepatitis B or C. Examples include: children born to parents who inject 
drugs, and who may later be placed in care or adopted, foreign students – 
or children who have been adopted – from a country with a medium or 
high background endemicity. Other, smaller groups who are at increased 
risk of chronic infection include people who have:  
 Received blood or a blood product transfusion prior to the 
introduction of hepatitis C virus screening of the blood supply 
(1991) or prior to the introduction of heat treatment for clotting 
factor concentrates (1986).   
 Received medical or dental procedures abroad where infection 
control may be inadequate. 
 Been exposed to unsterile needles (for example, by having 
non-professional tattoos, body or ear piercing, or acupuncture. 
3.42 The PDG noted the importance of ascertaining the identity of individuals 
being tested for hepatitis B and C. Members had been made aware of 
instances where NHS cards have been passed on or sold to illegal 
migrant workers by some Chinese immigrants. In some cases medical 
information has, as a result, been linked to the wrong people with 
potentially hazardous consequences.  
3.43 The PDG emphasised existing hepatitis B vaccination recommendations 
(as detailed in the Green book) because, although hepatitis B vaccination 
was beyond the scope of this guidance, case-finding may identify people 
who should be vaccinated.   
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3.44 In addition, the Group was aware of the complexities of the vaccination 
schedule for babies born to infected mothers. Specifically, members were 
aware of the apparent failure of the system to ensure babies receive a full 
course of vaccination and then have their immunity confirmed.  
3.45 Staff working in drugs services have a diverse mix of skills. As a result, it 
would not be possible to adopt a universal approach to training them in 
hepatitis B and C testing. However, the PDG felt that all staff should be 
capable of encouraging people to have a test. 
3.46 The PDG focused on people who inject drugs and migrants from medium 
and high endemicity countries. The Group noted that effective testing has 
already been implemented for other groups at increased risk, including 
men who have sex with men and people with multiple sexual partners. For 
other populations at increased risk there was no evidence that infection 
rates were sufficiently high to warrant a recommendation. (These groups 
include those who have been exposed to unsterile needles, for example, 
by having non-professional tattoos, body or ear piercing, or acupuncture.) 
This section will be completed in the final document. 
4 Implementation 
NICE guidance can help: 
 Commissioners and providers of NHS organisations, social care and children's 
services meet national priorities and the requirements of the DH's 'Operating 
framework for 2011/12'. 
 National and local organisations improve quality and health outcomes and reduce 
health inequalities. 
 Local authorities improve the health and wellbeing of people in their area. 
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 Local NHS organisations, local authorities and other local partners benefit from 
any identified cost savings, disinvestment opportunities or opportunities for re-
directing resources. 
 Provide a focus for integration and partnership working across social care, the 
NHS and public health organisations. 
NICE will develop tools to help organisations put this guidance into practice. Details 
will be available on our website after the guidance has been issued.  
5 Recommendations for research  
The Programme Development Group (PDG) recommends that the following research 
questions should be addressed. It notes that ‘effectiveness’ in this context relates not 
only to the size of the effect, but also to cost effectiveness and duration of effect. It 
also takes into account any harmful/negative side effects.  
5.1 How many children in the UK are infected with chronic hepatitis B and C 
and which subgroups of the population do they come from? 
5.2 What factors influence whether or not specific groups at increased risk of 
hepatitis B and hepatitis C infection are identified and tested?  
5.3 What factors influence whether or not specific high-risk groups will comply 
with treatment following a positive hepatitis B or C test?  
5.4 What are the most effective ways of getting people from high-risk groups 
involved in awareness-raising about, and promoting testing for, hepatitis B 
and C infection? 
5.5 Which interventions aimed at healthcare practitioners are effective at 
increasing the number of high-risk people who are tested and treated for 
hepatitis B and C?  
5.6 What impact does increased knowledge and awareness of hepatitis B and 
C among the general public have on the uptake of testing and treatment?  
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5.7 Which interventions for other communicable diseases could be effectively 
used to encourage people at increased risk of hepatitis B and C to take up 
the offer of testing and treatment?   
5.8 What is the most cost effective method for contact tracing following 
notification of a new case of hepatitis B or C? 
More detail on the gaps in the evidence identified during development of this 
guidance is provided in appendix D. 
6 Updating the recommendations  
This section will be completed in the final document.  
7 Related NICE guidance 
Published  
Hepatitis C (genotype 1) - boceprevir. NICE technology appraisal 253 (2012) 
Hepatitis C (genotype 1) - telaprevir. NICE technology appraisal 252 (2012)   
Tuberculosis – hard to reach groups. NICE public health guidance 37 (2012)  
Increasing the uptake of HIV testing among men who have sex with men. NICE 
public health guidance 34 (2011)  
Increasing the uptake of HIV testing among black Africans in England. NICE public 
health guidance 33 (2011)  
Hepatitis C – peginterferon alfa and ribavirin. NICE technology appraisal 200 (2010)  
Hepatitis B – tenofovir disoproxil fumarate. NICE technology appraisal 173 (2009)  
Reducing differences in the uptake of immunisations. NICE public health guidance 
21 (2009)  
Needle and syringe programmes. NICE public health guidance 18 (2009)  
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Antenatal care. NICE clinical guideline 62 (2008)  
Hepatitis B – telbivudine. NICE technology appraisal 154 (2008)  
Hepatitis B – entecavir. NICE technology appraisal 153 (2008)  
Prevention of sexually transmitted infections and under-18 conceptions. NICE public 
health guidance 3 (2007)  
Hepatitis C – peginterferon alfa and ribavirin. NICE technology appraisal 106 (2006)  
Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a. NICE 
technology appraisal 96 (2006)  
Hepatitis C – pegylated interferons, ribavirin and alfa interferon. NICE technology 
appraisal 75 (2004)  
Under development 
Hepatitis B: diagnosis and management. NICE clinical guideline (publication 
expected June 2013) 
8 Glossary  
Close contacts 
The people in close contact with someone infected with hepatitis B or C virus, where 
there is a risk of spreading the infection (via blood or body fluids). This could include 
their family members, close friends, household contacts or sexual partners. 
Continuity of care 
Continuation of treatment and referral for treatment for people moving in, out or 
between prisons.  
Household contact 
A person sharing a bedroom, kitchen, bathroom or sitting room with the index case. 
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Locally enhanced services  
Additional services provided by GPs, designed to meet specific local health needs.  
Medical hold 
A process to ensure prisoners are not transferred until they are medically fit enough. 
NHS deaneries  
Bodies responsible for managing and delivering postgraduate education and  
continuing professional development for medical staff. 
Peers 
Peers are members of the target population who have experienced hepatitis B 
and/or hepatitis C.  They are often in a good position to help convey, with empathy, 
the need for testing or treatment. They may be recruited and supported to 
communicate health messages, assist with contact investigations or testing, and to 
offer people support while they are being tested or treated.  
Prison 
Her Majesty’s prison establishments, including young offender institutions.  
In-reach model 
Healthcare services are brought into the prison, rather than the prisoner being taken 
out to the healthcare service (for example, to a hospital outpatient unit). 
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Appendix A Membership of the Programme Development 
Group (PDG), the NICE project team and external 
contractors 
Programme Development Group 
PDG membership is multidisciplinary. The Group comprises academics, clinicians, 
local authority officers, public health practitioners, social care professionals, 
teachers, technical experts and representatives of the public, as follows.  
Vijay Anad GP, Worcester 
Neil Connelly Community Member 
Daniela De Angelis Programme Leader, Medical Research Council Biostatistics 
Unit, Institute of Public Health, Cambridge 
Kate Drysdale Clinical Nurse Specialist, Dudley Group Community Services  
Erika Duffell Expert in Surveillance for HIV, STI and Hepatitis, European Centre for 
Disease Prevention and Control (ECDC), Stockholm  
Opal Greyson Viral Hepatitis Specialist Nurse, NHS Bedford and Luton 
Richard Grieve Senior Lecturer in Health Economics, London School of Hygiene 
and Tropical Medicine 
Matt Hickman (Chair) Professor in Public Health and Epidemiology, School of Social 
Community Medicine, University of Bristol  
Will Irving Professor and Honorary Consultant in Virology, University of Nottingham 
and Nottingham University Hospitals NHS Trust  
Emily Kam-Yin Lam Community Member 
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Deirdre Kelly Professor of Paediatric Hepatology, Birmingham Children’s Hospital 
NHS Foundation Trust 
Salim Khakoo Professor of Hepatology, Imperial College, London  
Danny Morris Independent Consultant, UK Harm Reduction Alliance  
Cristina Osorio Community Member 
Kylie Reed Psychiatrist and Clinical Research Worker, National Addiction Centre  
April Wareham Community Member  
Helen Wilks (Co-Chair) National Needle Exchange Forum  
James Windsor Community Member  
Nat Wright Clinical Director Vulnerable Groups, NHS Leeds 
NICE project team 
Mike Kelly CPHE Director 
Antony Morgan Associate Director  
Kay Nolan Co-lead Analyst  
Clare Wohlgemuth Co-lead Analyst 
Hilary Chatterton Analyst 
James Jagroo Analyst 
Alastair Fischer Technical Adviser, Health Economics 
Victoria Axe Project Manager 
Melinda Kay Coordinator 
Sue Jelley Senior Editor 
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Alison Lake Editor 
External contractors 
Evidence reviews 
Review 1 was carried out by Liverpool John Moores University. The principal authors 
were: Lisa Jones, Amanda Atkinson, Lorna Porcellato, Geoff Bates, Ellie McCoy, 
Caryl Beyon, Jim McVeigh and Mark Bellis.  
Review 2 was carried out by Liverpool John Moores University. The principal authors 
were: Lisa Jones, Geoff Bates, Ellie McCoy, Caryl Beynon, Jim McVeigh and Mark 
Bellis. 
The mapping review was carried out by Liverpool John Moores University. The 
principal authors were: Lisa Jones, Geoff Bates, Ellie McCoy, Amy Luxton, Caryl 
Beynon, Jim McVeigh and Mark Bellis.   
Cost effectiveness 
The review of economic evaluations was carried out as part of review 2.  
Economic modelling was carried out by the London School of Hygiene and Tropical 
Medicine. It comprised two reports. The principal authors were: Natasha Martin, Alec 
Miners, Peter Vickerman and Anjan Ghosh.   
See appendix E for the titles of the above reports. 
Expert testimony 
Presentation 1 by Annie Mackie, UK National Screening Committee.  
Presentation 2 by Mary Ramsay, Health Protection Agency Centre for Infections. 
Presentation 3 by Dr Eamonn O’Moore, Health Protection Agency. 
Presentation 4 by Jaswant Sira, Birmingham Children's Hospital NHS Foundation 
Trust. 
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Presentation 5 by Jez Thompson, Royal College of General Practitioners. 
Presentation 6 by Magdalena Harris, London School of Hygiene and Tropical 
Medicine. 
Further expert testimony was given verbally by: 
Professor Martin Lombard, Department of Health 
Catherine Stephens, International Union of Sex Workers 
Jenny Wong (on behalf of Chinese interpreters), Manchester Chinese Centre. 
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Appendix B Summary of the methods used to develop this 
guidance 
Introduction 
The reviews and economic modelling report include full details of the methods used 
to select the evidence (including search strategies), assess its quality and 
summarise it.  
The minutes of the Programme Development Group (PDG) meetings provide further 
detail about the Group’s interpretation of the evidence and development of the 
recommendations. 
All supporting documents are listed in appendix E and are available at the NICE 
website.  
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Guidance development 
The stages involved in developing public health programme guidance are outlined in 
the box below.  
1. Draft scope released for consultation 
2. Stakeholder meeting about the draft scope 
3. Stakeholder comments used to revise the scope  
4. Final scope and responses to comments published on website 
5. Evidence reviews and economic modelling undertaken and submitted to PDG 
6. PDG produces draft recommendations 
7. Draft guidance (and evidence) released for consultation and for field testing 
8. PDG amends recommendations 
9. Final guidance published on website 
10. Responses to comments published on website 
Key questions 
The key questions were established as part of the scope. They formed the starting 
point for the reviews of evidence and were used by the PDG to help develop the 
recommendations. The overarching questions were: 
 Which interventions are effective and cost effective in encouraging people from 
high-risk groups to use services that currently (or potentially could) offer hepatitis 
B or C testing? 
 What prevents people in high-risk groups from seeking and accepting a hepatitis 
B or hepatitis C test? How do these factors differ for each group – and what 
factors increase the likelihood that they will seek and accept a test?   
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 Which interventions are effective and cost effective at overcoming the barriers to 
hepatitis B or C testing faced by high-risk groups and professionals? 
 What type of services and activities need to be commissioned to encourage 
people who have tested positive to continue to seek support?  
These questions were made more specific for each review (see reviews for further 
details). 
Reviewing the evidence  
Qualitative review 
One qualitative review was conducted (review 1). 
Identifying the evidence 
A number of databases were searched in March/April 2011 for qualitative studies 
exploring the views on, and experiences of, hepatitis B and C testing and treatment 
among those at greatest risk. Five journals with the highest yield of references were 
selected as follows:  
 Australian Health Review  
 Gastroenterology Nursing  
 International Journal of Drug Policy  
 Journal of Community Health  
 Journal of Viral Hepatitis.  
All journal issues (113) and supplements published between 2008 and 2011 were 
hand-searched. A number of websites were also searched. For details, see the 
review. 
Selection criteria 
Studies were included in review 1 if they considered:  
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 Groups at an increased risk of hepatitis B and C infection, their close contacts and 
practitioners who treat them or are involved in preventive activities.  
 Mixed ‘low’ and ‘high’-risk populations where it was possible to attribute the 
findings to particular high-risk populations. 
 The views and experiences of groups at increased risk towards case-finding, 
testing, communication of test results or subsequent treatment. 
 Patient and practitioner perspectives on the barriers to, and opportunities for, 
changing behaviour in relation to hepatitis B and C testing and subsequent care 
and treatment. 
Studies were excluded if they:  
 Focused solely on general population groups or groups at low risk of hepatitis B or 
C.  
 Used structured questionnaires as the sole method of data collection.  
 Only reported quantitative data not elicited from the patients or providers 
themselves. 
Effectiveness review 
One review of effectiveness was conducted (review 2). 
Identifying the evidence  
A number of databases were searched in July 2011 for studies from 1990 onwards.  
Selection criteria 
Studies were included in the effectiveness review if they:  
 Targeted groups at increased risk of hepatitis B and C infection. 
 Targeted healthcare professionals involved in hepatitis B and C testing and 
treatment. 
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 Aimed to raise awareness among people from high-risk groups of hepatitis B and 
C testing services. 
 Encouraged people from high-risk groups and their 'close contacts' to use 
hepatitis B and C testing services. 
 Improved access to testing services. 
Studies were excluded if they focused on changing the behaviour of people who 
inject drugs (in relation to injecting or sharing practices but without reference to case-
finding or testing).  
See each review for details of the inclusion and exclusion criteria. 
Quality appraisal 
Included papers were assessed for methodological rigour and quality using the NICE 
methodology checklist, as set out in the NICE technical manual ‘Methods for the 
development of NICE public health guidance’ (see appendix E). Each study was 
graded (++, +, –) to reflect the risk of potential bias arising from its design and 
execution. 
Study quality 
++  All or most of the checklist criteria have been fulfilled. Where they have not 
been fulfilled, the conclusions are very unlikely to alter. 
+  Some of the checklist criteria have been fulfilled. Those criteria that have not 
been fulfilled or not adequately described are unlikely to alter the conclusions. 
–  Few or no checklist criteria have been fulfilled. The conclusions of the study 
are likely or very likely to alter. 
The evidence was also assessed for its applicability to the areas (populations, 
settings, interventions) covered by the scope of the guidance. Each evidence 
statement concludes with a statement of applicability (directly applicable, partially 
applicable, not applicable).  
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Summarising the evidence and making evidence statements 
The review data was summarised in evidence tables (see full reviews).  
The findings from the reviews were synthesised and used as the basis for a number 
of evidence statements relating to each key question. The evidence statements were 
prepared by the external contractors (see appendix A). The statements reflect their 
judgement of the strength (quality, quantity and consistency) of evidence and its 
applicability to the populations and settings in the scope. 
Mapping review 
The mapping review comprised a survey of awareness-raising and other activities to 
encourage groups at increased risk of hepatitis B and C to seek support.  
Identifying the evidence 
Telephone interviews and an online questionnaire were used with healthcare 
professionals and representatives of voluntary and community sector organisations 
who work with those at higher risk of hepatitis B and C. See the review for details. 
Cost effectiveness 
There was a review of economic evaluations and two economic modelling exercises. 
Review of economic evaluations 
There was a review of economic evaluations as part of the effectiveness review 
(review 2). Studies were included if they reported both costs (regardless of how 
estimated) and outcomes (regardless of how specified).  
Economic modelling 
Three economic models were constructed to incorporate data from the reviews of 
effectiveness and cost effectiveness.  
A dynamic model was developed to estimate the cost effectiveness of interventions 
to promote hepatitis testing among people who inject drugs. The model had to be 
dynamic to account for the ongoing transmission of hepatitis C between people who 
inject drugs and secondary infections and transmission among others.   
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Two static models were developed to evaluate interventions aimed at migrant 
groups. (Hepatitis B and C case finding and treatment in the UK will have an effect 
on morbidity among those tested, but less impact on the incidence of chronic 
infection.)  
The results are reported in: ‘An economic evaluation of finding cases of hepatitis B 
and C infection in UK migrant populations’; and ‘Assessing the cost-effectiveness of 
interventions aimed at promoting and offering hepatitis C testing to injecting drug 
users: An economic modelling report’. 
Fieldwork 
This section will be completed in the final document.   
How the PDG formulated the recommendations 
At its meetings in May, July, September, November and December 2011 and 
February, March and April 2012, the Programme Development Group (PDG) 
considered the evidence, and cost effectiveness to determine:  
 whether there was sufficient evidence (in terms of strength and applicability) to 
form a judgement 
 where relevant, whether (on balance) the evidence demonstrates that the 
intervention or programme/activity can be effective or is inconclusive 
 where relevant, the typical size of effect (where there is one) 
 whether the evidence is applicable to the target groups and context covered by 
the guidance. 
The PDG developed draft recommendations through informal consensus, based on 
the following criteria: 
 Strength (type, quality, quantity and consistency) of the evidence. 
 The applicability of the evidence to the populations/settings referred to in the 
scope. 
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 Effect size and potential impact on the target population’s health. 
 Impact on inequalities in health between different groups of the population. 
 Equality and diversity legislation. 
 Ethical issues and social value judgements. 
 Cost effectiveness (for the NHS and other public sector organisations). 
 Balance of harms and benefits. 
 Ease of implementation and any anticipated changes in practice. 
Where possible, recommendations were linked to an evidence statement(s) (see 
appendix C for details). Where a recommendation was inferred from the evidence, 
this was indicated by the reference ‘IDE’ (inference derived from the evidence). 
. 
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Appendix C The evidence  
This appendix lists the evidence statements from two reviews, provided by external 
contractors (see appendix A and appendix E) and links them to the relevant 
recommendations. See appendix B for the meaning of the (++), (+) and (-) quality 
assessments referred to in the evidence statements.  
The two reviews are: 
 Review 1: ‘A systematic review of qualitative research on the views, perspectives 
and experiences of hepatitis B and C testing among practitioners and people at 
greatest risk of infection’. 
 Review 2: ‘A systematic review of the effectiveness and cost effectiveness of 
interventions aimed at raising awareness and engaging with groups who are at 
increased risk of hepatitis B and C infection’. 
The evidence statements are short summaries of evidence, in a review, report or 
paper (provided by an expert in the topic area). Each statement has a short code 
indicating which document the evidence has come from. The letter(s) in the code 
refer to the type of document the statement is from, and the numbers refer to the 
document number, and the number of the evidence statement in the document. 
Evidence statement Q1 indicates that the linked statement is numbered 1 in review 
1. Evidence statement E3 indicates that the linked statement is numbered 3 in 
review 2. 
The reviews and economic analysis are available online. Where a recommendation 
is not directly taken from the evidence statements, but is inferred from the evidence, 
this is indicated by IDE (inference derived from the evidence). 
Where the Programme Development Group (PDG) has considered other evidence, it 
is linked to the appropriate recommendation below. It is also listed in the additional 
evidence section of this appendix. 
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Recommendation 1: evidence statements: Q1, Q2, Q3, Q4, Q5, Q8, Q9, Q10, E1; 
IDE  
Recommendation 2: evidence statements: Q2, Q18, Q20, Q21, Q28, Q29, Q30, 
E2, E5, E8; IDE  
Recommendation 3: evidence statements: Q1, Q2, Q3, Q4, Q5, Q8, Q9, Q10, Q14, 
Q15, Q16, Q23, Q28, Q29, E1; IDE 
Recommendation 4: evidence statements: Q28, E5, E6, E11   
Recommendation 5: evidence statements: Q16, Q27, Q28, E1, E6; IDE 
Recommendation 6: evidence statements: Q18, Q20, Q21, Q24, Q25, Q28, Q29, 
Q30, E1, E4, E5, E6, E7, E8, E9; IDE  
Recommendation 7: IDE  
Recommendation 8: IDE 
Recommendation 9: IDE  
Recommendation 10: evidence statements: Q7, E5; IDE  
Evidence statements 
Please note that the wording of some evidence statements has been altered slightly 
from those in the evidence review(s) to make them more consistent with each other 
and NICE's standard house style. 
Evidence statement Q1 
Understanding and awareness of hepatitis B among people born in countries with 
intermediate and high endemicity may be strongly influenced by their personal 
experiences and cultural beliefs (two [++], one [+])1,2,3.  
1 Burke et al. 2004.  
2 Burke et al. 2011.  
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3 Wallace et al. 2011. 
Evidence statement Q2 
People born in countries with intermediate and high endemicity for hepatitis B may 
confuse the various forms of hepatitis and the relationship between hepatitis and 
HIV, and they may commonly hold inaccurate beliefs about transmission risks (two 
[++], one [+])1 2 3. The lack of, or gaps in, knowledge about hepatitis B identified 
among some healthcare professionals (two [++])4,3 may contribute to or compound 
inadequate knowledge about hepatitis B among groups at a high risk of infection. 
1 Burke et al. 2011.  
2 van der Veen et al. 2009.  
3 Wallace et al. 2011. 
4 Hwang et al. 2010.  
Evidence statement Q3 
People born in countries with intermediate and high endemicity for hepatitis B may 
commonly cite access to or contamination of food, or cultural practices associated 
with sharing food and communal eating, as the main cause of hepatitis B 
transmission (three [++] and one [+])1,2,3,4. Although vertical transmission of hepatitis 
B was acknowledged in some studies, sexual transmission of hepatitis B was 
infrequently mentioned; overall, the evidence suggests that groups at a high risk of 
infection do not perceive hepatitis B as an STI (three [++])4,5,6.  
1 Burke et al. 2004.  
2 Burke et al. 2011.  
3 Chen et al. 2006.  
4 Choe et al. 2005. 
5 van der Veen et al. 2009.  
6 Wallace et al. 2011. 
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Evidence statement Q4 
As with their beliefs about the causes and prevention of hepatitis B, people born in 
countries with intermediate and high endemicity may express beliefs about 
prevention that are influenced by their personal experiences and cultural background 
(four [++])1,2,3,4. Among people originating from East and South East Asia, prevention 
strategies may commonly reflect the practice of traditional medicine and vaccination 
may not generally be considered as a primary means of prevention (five [++] and one 
[+])1,2,5,6,7,8. Religious influences on preventive health strategies may also be 
apparent, for example among Muslim men (one [++])3.  
1 Choe et al. 2005.  
2 Chen et al. 2006. 
3 van der Veen et al. 2009. 
4 Wallace et al. 2011. 
5 Burke et al. 2004.  
6 Burke et al. 2011. 
7 Chang et al. 2008.  
8 Hwang et al. 2010. 
Evidence statement Q5 
Despite some participants expressing generally positive attitudes towards 
vaccination and people at high risk being receptive to vaccination (one [++] and one 
[+])1,2 some studies (two [++] and one [+])1,3,4 indicated that there is significant 
confusion and uncertainty surrounding vaccination among groups at a high risk of 
infection.  
1 Buck et al. 2006. 
2 van der Veen et al. 2009. 
3 Chen et al. 2006. 
4 Chang et al. 2008. 
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Evidence statement Q7 
Barriers to testing include an absence of clear symptoms of infection, practical 
obstacles such as inconvenience and time constraints, and language and cultural 
barriers, all of which may discourage some people from seeking care and may limit 
the role that healthcare providers play in providing education and outreach to 
immigrant communities (one [++])1.  
1 van der Veen et al. 2009. 
Evidence statement Q8 
The conception of hepatitis B as a ‘liver’ or ‘blood’ illness rather than a sexually 
transmitted infection (STI) appears to play an important role in tempering stigma 
associated with hepatitis B. Increasing awareness of hepatitis B as an STI was 
viewed by one study ([++])1as potentially contributing to increased stigma. 
1 van der Veen et al. 2009. 
Evidence statement Q9 
One study reported that people with a diagnosis of chronic hepatitis B, including first 
and second generation immigrants, had little recollection of providing consent to test 
and did not receive adequate information at diagnosis. This lack of information and 
knowledge was perceived as impacting negatively on their health and preventing 
opportunities for behaviour change. Both patients and community workers expressed 
concerns about a lack of provider knowledge with regards to hepatitis B (one [++])1. 
1 Wallace et al. 2011. 
Evidence statement Q10 
One study ([++])1 reported that people with a diagnosis of chronic hepatitis B, 
including first- and second-generation immigrants, had little recollection of providing 
consent to test and did not receive adequate information at diagnosis. This lack of 
information and knowledge was perceived as impacting negatively on their health 
and preventing opportunities for behaviour change. Both patients and community 
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workers expressed concerns about a lack of provider knowledge with regards to 
hepatitis B. 
1 Wallace et al. 2011. 
Evidence statement Q14 
There is strong evidence from 18 studies (eleven [++], five [+], one [-] and one 
[NR])1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18 that injecting drug users (IDUs) have an 
uncertain and incomplete knowledge of hepatitis C. Studies showed that IDUs are 
confused over what the disease is, how it differs from other forms of hepatitis, how 
the infection is transmitted and what symptoms are involved. This confusion was 
reinforced by the perception that expert and scientific knowledge on hepatitis C is 
shifting and uncertain (three [++] and one [NR])4,11,12,17. There is evidence that some 
IDUs are aware of their limited knowledge of hepatitis C (three [++])3,4,12. 
1 Copeland 2004.  
2 Coupland et al. 2009.  
3 Davis and Rhodes 2004.  
4 Davis et al. 2004.  
5 Ellard 2007.  
6 Fraser 2004.  
7 Fraser 2010.  
8 Gyarmathy et al. 2006.  
9 Harris 2009a.  
10 Munoz-Plaza et al. 2004.  
11 Rhodes and Treloar 2008.  
12 Rhodes et al. 2004.  
13 Sosman et al. 2005.  
14 Southgate et al. 2005.  
15 Sutton and Treloar 2007.  
16 Swan et al. 2010.  
17 Tompkins et al. 2005.  
18 Wright et al. 2005. 
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Evidence statement Q15 
Hepatitis C is often understood in relation to HIV in a way that trivialises the 
seriousness of contracting hepatitis C and may have implications for the use of safe 
injecting practices and the uptake of hepatitis C services (eleven [++], two [+] and 
two [NR])1,2,3,4,5,6,7,8,9,10,11,12,13,14,15.  
1 Copeland 2004.  
2 Davis and Rhodes 2004.  
3 Davis et al. 2004. 
4 Ellard 2007.  
5 Faye and Irurita 2003.  
6 Harris 2009a.  
7 Munoz-Plaza et al. 2010. 
8 Rhodes et al. 2004. 
9  Roy et al. 2007. 
10 Southgate et al. 2005. 
11 Sutton and Treloar 2007. 
12 Swan et al. 2010. 
13 Rhodes and Treloar 2008. 
14 Treloar and Rhodes 2009. 
15 Wozniak et al. 2007. 
Evidence statement Q16 
A number of barriers to hepatitis C testing among IDUs were identified. People 
perceiving themselves to be at low risk of hepatitis C infection, a lack of visible 
symptoms of hepatitis C infection, fear of a positive test result, the use of needles 
and fear of disclosure were found to prevent the uptake of hepatitis C testing among 
IDUs (seven [++], eight [+], one [-] and one [NR])1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17. Three 
studies(two [+] and one [-])7,18,19 reported barriers to testing specific to the prison 
setting including long waiting times, lack of information provision, prioritisation of 
detoxification and withdrawal, and movement between prisons.  
1 Craine et al. 2004.  
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2 Davis et al. 2004.  
3 Fraser 2004. 
4 Fraser 2010. 
5 Gyarmathy et al. 2006. 
6 Harris 2009a. 
7 Khaw et al. 2007. 
8 Lally et al. 2008. 
9 Perry et al. 2003. 
10 Rhodes and Treloar 2008. 
11 Rhodes et al. 2004. 
12 Temple-Smith et al. 2004. 
13 Sosman et al. 2005. 
14 Southgate et al. 2005. 
15 Strauss et al. 2008. 
16 Sutton and Treloar 2007. 
17 Swan et al. 2010. 
18 Dyer and Tolliday 2009.  
19 Munoz-Plaza et al. 2005b. 
Evidence statement Q18 
Convenient and opportunistic testing and a ‘one-stop shop’ approach for all hepatitis 
C services was regarded as a convenient approach among IDUs (three [++] and five 
[+])1,2,3,4,5,6,7,8. There is evidence (two [++] and two [+])3,9,10,11 that some IDUs were 
unaware that they had been tested for hepatitis C and concern over informed 
consent to testing was noted by a number of authors. Although an opportunistic 
approach can increase testing compliance, a lack of informed consent may also 
contribute towards uncertain knowledge of hepatitis C among IDUs and limit the 
impact of testing on behaviour. 
1 Gyarmathy et al. 2006. 
2 Munoz-Plaza et al. 2004. 
3 Rhodes et al. 2004. 
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4 Roy et al. 2007. 
5 Sosman et al. 2005. 
6 Swan et al. 2010. 
7 Strauss et al. 2008. 
8 Temple-Smith et al. 2004. 
9 Munoz-Plaza et al. 2005b. 
10 Perry and Chew-Graham 2003. 
11 Tompkins et al. 2005. 
Evidence statement Q20 
Trust and rapport with health professionals and drug treatment staff motivated 
people to get tested. Support and encouragement from health professionals also 
facilitated testing among IDUs (four [+])1,2,3,4.  
1 Munoz-Plaza et al. 2004. 
2 Perry et al. 2003. 
3 Sosman et al. 2005. 
4 Strauss et al. 2008. 
Evidence statement Q21 
Studies showed that the experience of being informed about the outcome of hepatitis 
C testing can be highly confusing (nine [++], two [+], one [-] and one 
[NR])1,2,3,4,5,6,7,8,9,10,11,12,13. Limited and inadequate information provision by health 
professionals can lead to confusion over the meaning of a positive diagnosis and 
substantial gaps in knowledge.  
1 Copeland 2004. 
2Cullen et al. 2005. 
3Faye and Irurita 2003. 
4Khaw et al. 2007. 
5Kinder 2009. 
6Lally et al. 2008. 
7Rhodes and Treloar 2008. 
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8Rhodes et al. 2004. 
9Southgate et al. 2005. 
10Strauss et al. 2008. 
11Sutton and Treloar 2007. 
12Swan et al. 2010. 
13Tompkins et al. 2005. 
Evidence statement Q23 
Fear of the side effects associated with hepatitis C treatment and the circulation of 
‘horror stories’ and unsuccessful treatment cases among peers discouraged IDUs 
from engaging with treatment (three [++], one [+] and two [-])1,2,3,4,5,6. A fear of 
needles was also common and using needles during the treatment process was a 
challenge to overcome when considering treatment (two [++] and one [+])3,5,7. In 
contrast, anxiety over hepatitis C, witnessing peers suffer from symptoms of hepatitis 
C infection and hearing stories of successful treatment cases among peers 
encouraged treatment uptake (two [++] and one [+])3,5,8.  
1 Cullen et al. 2005. 
2 Fraser 2010. 
3 Kinder 2009. 
4 Munoz-Plaza et al. 2008. 
5 Swan et al. 2010. 
6 Treloar and Holt 2008. 
7 Strauss et al. 2008. 
8 Munoz-Plaza et al. 2004. 
Evidence statement Q24 
Socioeconomic and family circumstances can lead to treatment being de-prioritised 
among IDUs (three[++] and one [-])1,2,3,4. Studies have shown that a preoccupation 
with drug use, chaotic lifestyles, long waiting times between appointments and 
employment contributed towards IDUs missing and forgetting treatment 
appointments, thus increasing the possibility of treatment dropout (three [++])1,3,5. 
The assumption of abstinence as a requirement for hepatitis C treatment and 
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continued substance use among IDUs acted as a barrier to treatment (six [++] and 
one [-])1,3,5,6,7,8,9  
1 Coupland et al. 2009. 
2 Fraser 2010. 
3 Swan et al. 2010. 
4 Treloar et al. 2010. 
5 Lally et al. 2008. 
6 Cullen et al. 2005. 
7 Roy et al. 2007. 
8 Wozniak et al. 2007. 
9 Wright et al. 2005. 
Evidence statement Q25 
Receiving support from family, partners and peers, starting family life and concerns 
over the impact of hepatitis C on significant others (for example partners and 
children) motivated IDUs to engage with hepatitis C treatment (three [++])1,2,3.  
1 Faye and Irurita 2003. 
2 Kinder 2009. 
3 Swan et al. 2010. 
Evidence statement Q27 
One study ([-])1 found that being in prison was viewed by health professionals as 
both a barrier and a facilitator for hepatitis C treatment. Transportation of prisoners 
between prisons and short sentences were viewed as interfering with the treatment 
process whereas the structured environment of prison and availability of peer 
support during treatment were regarded as beneficial. 
1 Dyer and Tolliday 2009. 
Evidence statement Q28 
Two studies found that a lack of access to treatment and a lack of information on 
treatment options act as barriers to hepatitis C treatment (two [++])1,2. Increasing 
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knowledge of hepatitis C through the provision of information by health professionals 
encouraged IDUs to consider their treatment options (one [++], two [+] and one  
[-])1,3,4,5.  
1 Swan et al. 2010. 
2 Treloar et al. 2010. 
3 Cullen et al. 2005. 
4 Munoz-Plaza et al. 2004. 
5 Munoz-Plaza et al. 2008. 
Evidence statement Q29 
The experience of stigma prevented IDUs from seeking hepatitis C testing because of 
fear of disclosure, and prevented IDUs from disclosing a positive hepatitis C status 
because of fear of a negative reaction, isolation and social exclusion (eight [++], three 
[+], one [-] and one [NR])1,2,3,4,5,6,7,8,9,10,11,12,13. Stigma also prevented engagement with 
further prevention education, investigations and treatment and resulted in IDUs 
receiving inadequate and judgemental care by health professionals (seven [++], six 
[+], one [-] and two [NR])5,6,7,9,12,14,15,16,17,18, 19,20,21,22, 23,24. 
1 Craine et al. 2004. 
2 Ellard 2007. 
3 Harris 2009b. 
4 Khaw et al. 2007. 
5 Lally et al. 2008. 
6 McCreaddie et al. 2011. 
7 Roy et al. 2007. 
8 Sosman et al. 2005. 
9 Strauss et al. 2008. 
10 Sutton and Treloar 2007. 
11 Tompkins et al. 2005. 
12 Treloar and Rhodes 2008. 
13 Wright et al. 2005. 
14 Carrier et al. 2005. 
Hepatitis B and C: ways to promote and offer testing Consultation draft   
  Page 64 of 76 
 
15 Coupland et al. 2009. 
16 Faye and Irurita 2003. 
17 Habib and Adorjany 2003. 
18 Munoz-Plaza et al. 2004. 
19 Paterson et al. 2007. 
20 Perry et al. 2003. 
21 Swan et al. 2010. 
22 Temple-Smith et al. 2004. 
23 Treloar and Hopwood 2004. 
24 Treloar et al. 2010. 
Evidence statement Q30 
Perceiving health care professionals to be supportive, concerned and caring, and 
being encouraged to undertake treatment by health professionals was found to 
motivate IDUs to engage in hepatitis C treatment (four [++], one [+] and one [-
])1,2,3,4,5,6. There was evidence across a number of studies that IDUs preferred 
hepatitis C services, including treatment, to be situated in one setting such as drug 
treatment programmes and methadone substitution settings (two [++] and one 
[+])5,7,6. These services were also seen as useful in providing information on hepatitis 
C treatment (one [++] and three [+])5,6,8,9  
1 Fraser 2010. 
2 Coupland et al. 2009. 
3 Kinder 2009. 
4 McCreaddie et al. 2011. 
5 Munoz-Plaza et al. 2004. 
6 Swan et al. 2010. 
7Treloar et al. 2010. 
8 Munoz-Plaza et al. 2005a. 
9 Munoz-Plaza et al. 2006. 
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Evidence statement E1 
There is moderate evidence from three RCTs (one [++] and two [+])1,2,3 and one 
uncontrolled (UBA) study (-)4 to suggest that providing information and education on 
hepatitis B to migrant populations may improve their knowledge about risk, screening 
and prevention; moderate evidence from three RCTs (one [++] and two [+])1,2,3 to 
suggest that providing information and education on hepatitis B to migrant 
populations does not improve testing uptake; and weak evidence from one case 
series (-)5 to suggest that testing supplemented with culturally appropriate education 
may encourage the uptake of follow-up care among migrant populations. 
1 Taylor et al. 2009a. 
2 Taylor et al. 2009b. 
3 Taylor et al. 2011. 
4 Hsu et al. 2007; 2010. 
5 Chao et al. 2009. 
Evidence statement E2 
There is moderate evidence from one RCT (+)1 to suggest that a strategy to promote 
cancer prevention activities among doctors serving migrant populations does not 
improve their practices in relation to hepatitis B testing. There is weak evidence from 
one UBA study (-)2 to suggest that providing information and education on hepatitis 
B to complementary and alternative medicine (CAM) practitioners (including those 
practising traditional Chinese medicine and acupuncture) may improve their 
knowledge about risk, screening and prevention. However, the wider impact of this 
change in knowledge on their practices regarding referral for testing is not clear. 
1 Nguyen et al. 2000. 
2 Chang et al. 2007. 
Evidence statement E4 
There is moderate evidence from one RCT (+)1 and one CBA study (-)2 to suggest 
that offering dried blood-spot (DBS) testing to IDUs attending substance misuse 
services may increase uptake of hepatitis C testing compared to venipuncture alone 
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being offered. The increase in uptake may reflect an increase in testing availability, 
as more staff can be trained to deliver DBS testing than venipuncture, as well as 
higher acceptability to IDUs. There is weak evidence from one CS study (-)3 to 
suggest that providing high-risk groups with access to DBS testing kits via a 
telephone hotline is not an effective use of resources compared to testing via state 
laboratories. 
1 Hickman et al. 2008. 
2 Craine et al. 2009. 
3 Rainey et al. 2005. 
Evidence statement E5 
There is moderate evidence from one RCT (+)1 to suggest that although providing 
GPs with both training and assistance with screening (through the use of patient-
targeted materials) may increase patient requests for testing, it does not impact upon 
the number of patients tested for hepatitis C overall. There is moderate evidence 
from two non-randomised controlled trials (NRCTs) (two [+])2,3 to suggest that 
targeted case finding in primary care for patients with a history of injecting drug use 
may have a positive impact on the number of patients who are offered and accept a 
hepatitis C test. Although the level of referral of patients identified with infection was 
relatively high, the number of subsequent dropouts prior to treatment indicates that 
there is a need for further support beyond the intervention offered in these studies. 
1 Roudot-Thoraval et al. 2000. 
2 Anderson et al. 2009. 
3 Cullen et al. in press. 
Evidence statement E6 
There is moderate evidence from one RCT (+) and two case series (two [-])1,2,3 to 
suggest that providing hepatitis C services in community settings may have a 
positive impact on testing acceptance and uptake. In particular, there is weak 
evidence from two case series (two [-])4,5 to suggest that a multidisciplinary or shared 
care approach to hepatitis C testing and treatment for IDUs is associated with high 
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uptake of follow-up services and treatment outcomes comparable with non-drug-
using populations. In two studies conducted in the USA (two [-])6,7, hepatitis testing 
was added to routine blood work undertaken on entry to drugs services and 
therefore a high testing rate was inevitable; There is moderate evidence from one 
RCT (+)8 to suggest that the provision of testing services via outreach may have a 
positive impact on testing acceptance and uptake. The impact may be greatest when 
testing is offered on-site rather than by referral; There is weak evidence from one 
UBA study (-)9 to suggest that the provision of hepatitis C outreach services for new 
prisoners may lead to relatively low uptake of testing. 
1 Rosenberg et al. 2010. 
2 Lindenberg et al. 2011. 
3Jack et al. 2009. 
4 Lindenberg et al. 2011. 
5 Jack et al. 2009. 
6 Harris et al. 2010. 
7 Hagedorn et al. 2007. 
8 Sahajian et al. 2011. 
9 Skipper et al. 2003. 
Evidence statement E7 
There is weak evidence from one case series (-)1 to suggest that offering a non-
invasive liver evaluation technique in outreach settings provides an opportunity to 
subsequently test IDUs for hepatitis C. There is weak evidence from one case series 
(-)2 that education by a peer outreach worker may improve short-term knowledge 
about hepatitis C transmission among IDUs. 
1 Foucher et al. 2009. 
2 Aitken et al. 2002. 
Evidence statement E8 
There is moderate evidence from one RCT (++)1, one NRCT (+)2 and one UBA study 
(-)3 to suggest that complex interventions that provide support to primary care 
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professionals in offers of hepatitis C testing may have a positive impact on testing 
acceptance and uptake. One repeated cross-sectional study (CSS) (+)4 
demonstrated that without support, offers of testing may increase, but not within the 
desired high-risk groups. There is weak evidence from three UBA studies (three [-
])1,5,6  to suggest that educational interventions aimed at health professionals may 
have short-term benefits on knowledge about hepatitis C. However, there is no clear 
evidence that an increase in knowledge leads to an increase in testing. Weak 
evidence from one UBA study (-)4 suggested that a CME programme had a limited 
impact on testing uptake. There is mixed evidence from two studies (one [++] and 
one[+])7 that examined the effectiveness of interventions aimed at professionals on 
treatment initiation; There is moderate evidence from a repeated CSS (+)4 that a 
national campaign had no impact on the management of drug users following a 
positive hepatitis C test. However, there is strong evidence from one RCT (++)1 that 
a complex intervention providing support in primary care had a positive impact on 
number of referrals and attendance at follow-up appointments after testing. 
1 Cullen et al. 2006. 
2 Helsper et al. 2010. 
3 Sahajian et al. 2004. 
4 Defossez et al. 2008. 
5 D’Souza et al. 2004. 
6 Fischer et al. 2000. 
7 Garrard et al. 2006. 
Evidence statement E9 
There is weak evidence from one CBA study (-)1 and one case series (-)2 to suggest 
that the provision of hepatitis C treatment in community settings for IDUs had a 
positive effect on treatment initiation and outcomes. There is weak evidence from 
two case series (both [-])3,4 that attendance at a support group for hepatitis C may 
have a positive effect on treatment initiation. However, it was unclear due to the 
study design used whether attendance at the support group was higher among more 
highly motivated individuals who may have been more likely to initiate treatment 
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regardless of their attendance at the group. There is weak evidence from one cohort 
study (-)5 to suggest that allowing patients, such as those who have not been 
referred by their doctor, to self-refer to speciality liver clinics for assessment was 
associated with treatment uptake and completion at rates similar to those referred by 
health professionals. There is weak evidence from a CBA study (-)6 to suggest that 
ensuring patients receive education about hepatitis C prior to referral appointments 
may have a positive effect on attendance at follow-up appointments, and on short to 
medium-term knowledge.  
1 Moussalli et al. 2010. 
2 Wilkinson et al. 2008. 
3 Grebely et al. 2007. 
4 Grebely et al. 2010. 
5 Doucette et al. 2009. 
6 Surjadi et al. 2011. 
Evidence statement E11 
There is moderate evidence from one cost utility analysis (CUA) (+)1 to suggest that 
community-based screening and treatment for hepatitis B among migrant 
populations is cost-effective. 
1 Veldhuijzen et al. 2010. 
Additional evidence 
A mapping review was also carried out. This was a practice survey of activities and 
interventions that aim to raise awareness among, and/or engage with, groups who 
are at an increased risk of hepatitis B and C infection. 
Economic modelling  
There were three models. One model looked at three scenarios for increasing testing 
for hepatitis C among people who inject drugs and people who used to inject drugs, 
with the emphasis on training and education:  
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 Training specialist addiction services in the community to undertake dried blood-
spot testing for chronic hepatitis C. 
 Educating GPs about the infection. 
 Training prison nurses to undertake dried blood-spot testing for chronic hepatitis 
C.  
Training for dried blood-spot testing in the community resulted in a substantially 
greater proportion of cases of chronic hepatitis C being identified, compared with not 
offering this blood sampling method. This lead to an estimated cost per quality of life 
years (QALY) gained of £15,000, which is below the threshold of £20,000 generally 
accepted by NICE as cost effective.  
Educating GPs about chronic hepatitis C also resulted in an increase in testing and 
was also cost effective, yielding an estimated cost per QALY of £14,000. Training 
prison nurses to undertake dried blood-spot testing also increased the proportion of 
chronic hepatitis C cases found, compared to not offering this sampling method. 
However, the cost effectiveness of this training depended on whether the resulting 
treatment was completed. In such cases, the estimated cost per QALY gained was 
£10,000. If the treatment was halted at any point, the cost per QALY of finding a new 
case was estimated to rise to £59,000 per QALY and thus, was not cost effective. 
The estimated cost per QALY will be less than £20,000 per QALY gained if treatment 
is seamlessly completed in at least 40% of cases. 
A second model looked at finding and testing UK migrants for chronic hepatitis C. 
This was found to be cost effective if 2% of the population group were infected and it 
cost no more than £20 to find and test each person. In such a case, the cost per 
QALY gained was estimated at £10,000. If the cost of finding and testing someone 
was £50, the estimated cost per QALY was still cost effective – at £18,000. It 
became more cost effective to find and test people if more than 2% of the population 
group were infected – and it cost no more than £20 per person to find and test them.  
A third model looked at finding and testing UK migrants for chronic hepatitis B. If 
there was a 2% prevalence within the population group and it cost £20 to find and 
test each infected person, the estimated cost per QALY gained would be £21,000, 
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marginally above the NICE £20,000 threshold for cost effectiveness.  However, it 
would be cost effective if the prevalence of infection was 3% or higher. At 20% 
prevalence, as is believed to be the case among some migrant groups, the 
estimated cost per QALY of finding and testing people falls to £12,000 and was, 
therefore, deemed cost effective.  
Based on the modelling, the PDG considered that it would be cost effective to 
simultaneously find and test people at risk for both hepatitis B and C, provided there 
was a 2% prevalence of both infections and it cost up to £75 to find and test each 
person. 
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Appendix D Gaps in the evidence 
The Programme Development Group (PDG) identified a number of gaps in the 
evidence related to the programmes under examination, based on an assessment of 
the evidence. These gaps are set out below.  
1. There is a lack of robust, quantitative studies on identifying, testing and 
treating hepatitis B and C (that is, studies that are applicable to the UK 
context). In particular there is a lack of: 
a) Reliable data on the number of people in the UK with chronic hepatitis 
B and C. In particular, there is no national information on the number of 
children infected. 
b) Reliable local information on the number of people with chronic 
hepatitis B and C. 
c) Interventions to increase hepatitis B and C testing among migrant 
populations. 
d) Interventions to increase hepatitis B and C testing in non-health 
settings, for example, prisons. 
e) Data looking at injecting drug use as a transmission route for hepatitis 
B. 
2. There is a lack of qualitative studies on hepatitis B and C, including studies 
focused on: 
a) Cultural issues which may act as a barrier to testing and treatment. 
b) Knowledge of, barriers against and facilitators for hepatitis C testing 
and treatment among migrant populations. 
c) Knowledge of, barriers against and facilitators for preventing 
hepatitis B and C among men who have sex with men.  
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d) Knowledge of, barriers against and facilitators for preventing 
maternal transmission of hepatitis B.  
e) Knowledge of, barriers against and facilitators for preventing 
hepatitis B among injecting drug users.   
f) How former drug users, both from a service user and provider 
perspective, regard testing for hepatitis.  
g) The views, perspectives and experiences of hepatitis B and C testing 
among people whose past behaviour has put them at risk but who 
choose not to disclose this information. This includes people who 
have previously injected drugs or worked as commercial sex 
workers.  
h) The views, perspectives and experiences of hepatitis B and C testing 
among practitioners and people at increased risk of infection, 
according to level and type of practitioner knowledge.  
i) Prisoners’ views of hepatitis testing and treatment and the views of 
those working with them. 
j) The acceptability of different types of hepatitis test. 
k) Factors which encourage people to have a liver biopsy or discourage 
them from this. 
l) The knowledge GPs need to be able to identify people at-risk and to 
be able to test and treat them.    
m) Why people referred by GPs for a hepatitis test drop out and whether 
or not an integrated services/one-stop-shop approach to see if this 
improves uptake rates. 
n) Understanding of hepatitis B and C care pathways generally and 
linked to the use of laboratory services.  
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3. There is a lack of evidence on the role of the voluntary sector in promoting 
and offering tests for hepatitis B and C. 
4. There is a lack of evidence on what is happening in the ‘real world’. This 
includes the views of those: 
o) at risk of hepatitis B and C 
p) who have been identified and/or tested and/or treated 
q) who have dropped out at different stages of the care pathway. 
5. There is a lack of qualitative and quantitative evidence on the acceptability of 
non-invasive approaches to testing among different communities. 
6. There is a lack of evidence on how hepatitis B and C status could be 
assessed when testing for other diseases and blood-borne viruses. 
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Appendix E Supporting documents 
Supporting documents include the following. 
 Evidence reviews:  
 Review 1: ‘A systematic review of qualitative research on the views, 
perspectives and experiences of hepatitis B and C testing among 
practitioners and people at greatest risk of infection’ 
 Review 2: ‘A systematic review of the effectiveness and cost 
effectiveness of interventions aimed at raising awareness and 
engaging with groups who are at increased risk of hepatitis B and C 
infection’ 
 Mapping review: ‘A practice survey of activities and interventions that 
aim to raise awareness among, and/or engage with, groups who are 
at an increased risk of hepatitis B and C infection’. 
 Economic modelling:  
  ‘An economic evaluation of finding cases of hepatitis B and C 
infection in UK migrant populations’ 
  ‘Assessing the cost-effectiveness of interventions aimed at 
promoting and offering hepatitis C testing to injecting drug users: An 
economic modelling report’. 
 Expert testimony:  
 Presentation 1: ‘UK National screening Committee and case finding 
versus screening’ 
 Presentation 2: ‘Hepatitis B vaccination in England and Wales’ 
 Presentation 3: ‘Hepatitis testing in prisons’  
 Presentation 4: ‘Paediatric hepatitis testing and treatment’  
 Presentation 5: ‘The role of GPs in promoting hepatitis B and C 
testing among at risk populations’  
 Presentation 6: ‘Perspective on barriers to hepatitis testing and 
treatment for people who inject drugs’.  
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For information on how NICE public health guidance is developed, see: 
 ‘Methods for development of NICE public health guidance (second edition, 2009)’ 
 ‘The NICE public health guidance development process: An overview for 
stakeholders including public health practitioners, policy makers and the public 
(second edition, 2009)’.  
